Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.530
-0.160 (-9.47%)
At close: Nov 1, 2024, 4:00 PM
1.560
+0.030 (1.96%)
After-hours: Nov 1, 2024, 5:45 PM EDT

Taysha Gene Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
12.8715.452.5---
Revenue Growth (YoY)
34.05%517.55%----
Gross Profit
12.8715.452.5---
Selling, General & Admin
29.630.0537.3641.3211.110.51
Research & Development
60.3356.7891.17131.9431.893.95
Operating Expenses
89.9386.83128.53173.27434.46
Operating Income
-77.06-71.37-126.03-173.27-43-4.46
Interest Expense
-2.24-5-3.8-1.43-0.03-
Interest & Investment Income
6.163.570.250.170.05-
Other Non Operating Income (Expenses)
-38.74-36.3-0.02--17.03-
EBT Excluding Unusual Items
-111.87-109.1-129.59-174.52-60.01-4.46
Asset Writedown
-1.07-1.07-36.42---
Other Unusual Items
-1.4-1.4----
Pretax Income
-114.34-111.57-166.01-174.52-60.01-4.46
Net Income
-114.34-111.57-166.01-174.52-60.01-4.46
Net Income to Common
-114.34-111.57-166.01-174.52-60.01-4.46
Shares Outstanding (Basic)
20011644381810
Shares Outstanding (Diluted)
20011644381810
Shares Change (YoY)
256.03%164.20%16.74%113.13%83.53%-
EPS (Basic)
-0.57-0.96-3.78-4.64-3.40-0.46
EPS (Diluted)
-0.57-0.96-3.78-4.64-3.40-0.46
Free Cash Flow
-75.73-76.89-109.01-132.35-30.81-
Free Cash Flow Per Share
-0.38-0.66-2.48-3.52-1.74-
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-598.62%-461.94%-5037.05%---
Profit Margin
-888.18%-722.06%-6635.25%---
Free Cash Flow Margin
-588.25%-497.62%-4356.87%---
EBITDA
-75.72-70-124.86-172.78-42.99-
D&A For EBITDA
1.341.371.170.490.01-
EBIT
-77.06-71.37-126.03-173.27-43-4.46
Source: S&P Capital IQ. Standard template. Financial Sources.